Jeff Yass’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-177,200
| Closed | -$6.67M | – | 13721 |
|
|
2021
Q1 | $6.67M | Buy |
177,200
+114,700
| +184% | +$2.86M | ﹤0.01% | 3405 |
|
|
2020
Q4 | $1.06M | Buy |
+62,500
| New | +$783K | ﹤0.01% | 6584 |
|
|
2020
Q2 | – | Sell |
-14,000
| Closed | -$32K | – | 11343 |
|
|
2020
Q1 | $32K | Buy |
+14,000
| New | +$59.4K | ﹤0.01% | 9819 |
|
|
2019
Q4 | – | Sell |
-122,200
| Closed | -$474K | – | 11062 |
|
|
2019
Q3 | $474K | Buy |
122,200
+90,900
| +290% | +$499K | ﹤0.01% | 7422 |
|
|
2019
Q2 | $189K | Buy |
31,300
+1,300
| +4% | +$12.4K | ﹤0.01% | 9173 |
|
|
2019
Q1 | $402K | Sell |
30,000
-7,600
| -20% | -$86.7K | ﹤0.01% | 6690 |
|
|
2018
Q4 | $350K | Sell |
37,600
-37,300
| -50% | -$444K | ﹤0.01% | 6728 |
|
|
2018
Q3 | $1.04M | Buy |
74,900
+34,800
| +87% | +$518K | ﹤0.01% | 5138 |
|
|
2018
Q2 | $634K | Sell |
40,100
-14,400
| -26% | -$251K | ﹤0.01% | 6336 |
|
|
2018
Q1 | $936K | Buy |
54,500
+10,100
| +23% | +$197K | ﹤0.01% | 5379 |
|
|
2017
Q4 | $973K | Sell |
44,400
-31,200
| -41% | -$1M | ﹤0.01% | 5294 |
|
|
2017
Q3 | $3.09M | Buy |
75,600
+39,200
| +108% | +$1.23M | ﹤0.01% | 3189 |
|
|
2017
Q2 | $1.1M | Buy |
36,400
+2,100
| +6% | +$65.5K | ﹤0.01% | 5067 |
|
|
2017
Q1 | $1.24M | Buy |
+34,300
| New | +$1.51M | ﹤0.01% | 4685 |
|
|
2016
Q4 | – | Sell |
-55,200
| Closed | -$2.9M | – | 10385 |
|
|
2016
Q3 | $2.9M | Sell |
55,200
-10,100
| -15% | -$482K | ﹤0.01% | 2959 |
|
|
2016
Q2 | $2.7M | Sell |
65,300
-4,200
| -6% | -$183K | ﹤0.01% | 3084 |
|
|
2016
Q1 | $2.82M | Sell |
69,500
-55,700
| -44% | -$1.91M | ﹤0.01% | 3156 |
|
|
2015
Q4 | $5.2M | Buy |
125,200
+106,900
| +584% | +$3.58M | ﹤0.01% | 2494 |
|
|
2015
Q3 | $282K | Buy |
18,300
+1,700
| +10% | +$36.5K | ﹤0.01% | 8146 |
|
|
2015
Q2 | $412K | Buy |
+16,600
| New | +$370K | ﹤0.01% | 7997 |
|
Jeff Yass's FPRX Position: Q2 2021 in Review
Jeff Yass sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 29,986 shares — an estimated $1.13M sold.
Jeff Yass first reported a position in FPRX in Q1 2015 and held it in 10 quarters. The position peaked at $1.13M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Jeff Yass reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Jeff Yass sold 29,986 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.13M.
- Jeff Yass first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
- Jeff Yass's Five Prime Therapeutics, Inc. position peaked at $1.13M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Susquehanna International Group's 13F filing for Q2 2021, filed 11 Aug 2021.